OncoMatch/Clinical Trials/NCT06159478
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
Is NCT06159478 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Binimetinib 15 MG for low-grade glioma.
Treatment: Binimetinib 15 MG — This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Pancreatic Cancer
Biomarker criteria
Required: BRAF fusion
BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical treatment, or clinical study (including liquid biopsy).
Required: BRAF rearrangement
BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical treatment, or clinical study (including liquid biopsy).
Disease stage
Grade: 12 (who)
Demographics
Prior therapy
Must have received: chemotherapy
Having progression after at least one regimen of chemotherapy excluding adjuvant therapy.
Cannot have received: MEK inhibitor (binimetinib)
Prior treatment with MEK inhibitors.
Lab requirements
Blood counts
Absolute neutrophil count >= 1,500/mm3; Platelet count >= 10.0 x 10^4/mm3; Hemoglobin >= 8.0 g/dL
Kidney function
Serum creatinine <= 1.5 mg/dL
Liver function
Total bilirubin <= 1.5 g/dL; AST <= 100 U/L; ALT <= 100 U/L
Cardiac function
Left ventricular ejection fraction >= 50% by echocardiography or MUGA within 28 days before registration; No cardiac effusion, pleural effusion, or ascites requiring treatment; No symptomatic congestive heart failure of NYHA class II-IV or arrhythmia (over grade 2) occurring in less than 6 months before registration; No myocardial infarction or unstable angina occurring in less than 6 months before registration; Corrected QT interval (QTcF) <= 480 ms in ECG performed within 14 days before enrollment.
Left ventricular ejection fraction >= 50% by echocardiography or MUGA (multigated acquisition scan) within 28 days before registration; No cardiac effusion, pleural effusion, or ascites requiring treatment; Laboratory tests within 14 days before registration and the values are within the following range. Patients should not receive administration of G-CSF and/or blood transfusion within 14 days before the blood collection (1) Absolute neutrophil count >= 1.500/mm3 (2) Platelet count >= 10.0 X 10(4))/mm3 (3) Hemoglobin >= 8.0 g/dL (4) Total bilirubin <= 1.5 g/dL (5) Aspartate aminotransferase (AST) <= 100 U/L (6) Alanine aminotransferase (ALT) <= 100 U/L (7) Serum creatinine <= 1.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06159478 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MEK inhibitor disqualifies patients from enrollment.
Does this trial require BRAF?
Yes, BRAF fusion is a required biomarker for enrollment.
Does this trial require BRAF?
Yes, BRAF rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages